Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405;
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorErdogan, Bulent
dc.contributor.authorTurkmen, Esma
dc.contributor.authorTozkir, Hilmi
dc.contributor.authorAlbayrak, Dogan
dc.contributor.authorUzunoglu, Sernaz
dc.date.accessioned2024-06-12T11:15:26Z
dc.date.available2024-06-12T11:15:26Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of this study was to investigate the clinicopathological characteristics and distribution by tumor localization of KRAS point mutations in metastatic colorectal cancer. A total of 189 patients diagnosed with colorectal cancer between 2007 and 2014, who were either metastatic at the time of diagnosis or developed metastasis subsequently, were included in this study. KRAS mutation analysis was performed in the primary tumor tissues and KRAS mutations were identified in 47.6% of the patients. There was a high frequency of the p.G13D point mutation in left-colon tumors (P=0.011), while the p.G12D point mutation was more frequent in right-colon tumors (P=0.004). KRAS wild-type frequency (P=0.02) was higher among patients aged <40 years. A comparison of codon 12 and 13 mutations revealed that codon 12 mutations were more common in the >50-year-old group (P=0.03) and codon 13 mutations were more common in the <70-year-old group (P=0.04). KRAS wild-type tumors were localized in the right colon (P=0.005) and tumors with the p.G13D point mutation (P=0.018) were diagnosed at non-metastatic stages. In conclusion, KRAS point mutations in colorectal cancer exhibited a heterogeneous distribution in terms of tumor localization. In addition, the p.G13D point mutation was found to differ from other mutations in several aspects.en_US
dc.identifier.doi10.3892/mco.2014.448
dc.identifier.endpage184en_US
dc.identifier.issn2049-9450
dc.identifier.issn2049-9469
dc.identifier.issue1en_US
dc.identifier.pmid25469291en_US
dc.identifier.startpage179en_US
dc.identifier.urihttps://doi.org/10.3892/mco.2014.448
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23936
dc.identifier.volume3en_US
dc.identifier.wosWOS:000453152500030en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpandidos Publ Ltden_US
dc.relation.ispartofMolecular And Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSpecific KRAS Mutationen_US
dc.subjectColorectal Canceren_US
dc.subjectTumor Locationen_US
dc.titleAssociation between specific KRAS mutations and the clinicopathological characteristics of colorectal tumorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu